Q4 2024 Pacific Biosciences of California Inc Earnings Call Transcript
Key Points
- Pacific Biosciences of California Inc (PACB) reported $39.2 million in revenue for Q4 2024, driven by the shipment of 23 Revvio systems and the successful early shipment of 7 Vega benchtop platforms.
- The company saw a significant expansion in its customer base, with nearly 200 customers using the Revo platform by the end of 2024.
- Consumable revenue grew 11% year-over-year in 2024 to $70.4 million, representing a 23% compound annual growth rate since 2020.
- The company anticipates sustained double-digit revenue growth in the medium term as long-read sequencing expands into new genomic applications.
- PACB successfully reduced annualized non-GAAP operating expenses by more than $75 million in 2024, aligning spending with strategic priorities.
- Instrument revenue in Q4 2024 was $15.3 million, a 56% decrease from the same quarter in 2023, primarily due to lower Revvio system shipments.
- The company faces an uncertain funding environment, particularly in the United States, due to macroeconomic pressures and recent NIH funding announcements.
- PACB recorded non-cash impairment charges totaling $90 million in Q4 2024, driven by macroeconomic headwinds and a revised outlook on future cash flows.
- The company expects 2025 revenue growth to be modest, with a forecasted range of $155 million to $170 million, reflecting only a 6% year-over-year growth at the midpoint.
- PACB has pushed out its timeline to become cash flow positive to exiting 2027, citing continued macroeconomic uncertainty and recent NIH announcements.
Good day and welcome to the PacBio fourth quarter of 2024 earnings conference call. (Operator Instructions) Please note today's event is being recorded.
I would now like to turn the conference over to Todd Friedman, senior director of finance and Investor Relations. Please go ahead.
Good afternoon and welcome to PacBio fourth quarter of 2024 earnings conference call. Earlier today, we issued a press release outlining the financial results we'll be discussing on today's call, a copy of which is available on the investors section of our website at www.Ab.com or as furnished on Form AK available on the Securities and Exchange Commission website at www.sec.gov. A copy of our earnings presentation is also available on the investors section of our website.
With me today are Christian Henry, President and Chief Executive Officer; and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
